All In Biotech

Drug Trial Radar · NCT06556173

Phase 2a Study of VTX3232 in Parkinson's Disease

A Phase 2a, Single Site, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VTX3232 in Participants With Early-Stage Parkinson's Disease

Last checked: Nov 19, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

11

Actual

Start

Aug 8, 2024

Primary completion

Apr 4, 2025

Study completion Apr 4, 2025

Sponsor

Lead sponsor
Zomagen Biosciences Ltd.Industry
Sponsor type
Industry
First posted
Aug 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to understand if taking VTX3232 is safe in participants diagnosed with early stage idiopathic Parkinson's Disease (PD). Approximately 10 patients will take VTX3232 Dose A. The study consists of a 30-day Screening Period (to see if a participant qualifies for the study), a 7-day Pre-Baseline Period, a 28-day Open Label Treatment period (a participant receives active Dose A), and a 14-day Follow-Up Period.

Conditions

  • Idiopathic Parkinson Disease

Interventions

  • VTX3232Drug

    Dose A

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Event (AE) / Serious Adverse Event (SAE) Incidence Rate and Severity through study completionTime frame: Day 1 of treatment period through study completion, up to 6 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Local Site #840001

    New Haven, Connecticut

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.